{
    "hands_on_practices": [
        {
            "introduction": "The clinical manifestations of *Helicobacter pylori* infection are remarkably diverse, ranging from duodenal ulcers driven by acid hypersecretion to gastric atrophy and cancer associated with hypochlorhydria. Understanding which disease pathway will develop hinges on appreciating the distinct physiological consequences of infection in different regions of the stomach. This exercise challenges you to apply first principles of gastric endocrine regulation to a clinical vignette, deducing the pattern of gastritis from the patient's signs and symptoms .",
            "id": "4647810",
            "problem": "A 38-year-old man has recurrent epigastric pain relieved by food and presents with a bleeding duodenal ulcer. Endoscopy shows a clean-based ulcer in the first portion of the duodenum and biopsies from the gastric antrum are positive for *Helicobacter pylori* (*H. pylori*). His basal acid output (BAO) measured by nasogastric aspirate is elevated at 12 mEq/h, and fasting serum gastrin is modestly elevated. Atrophic changes are not seen in random biopsies from the proximal gastric corpus, and intrinsic factor antibodies are negative. \n\nFrom first principles of gastric physiology, consider the following core facts as the base:\n- Gastric acid secretion by parietal cells depends on stimulatory inputs from gastrin ($G$) secreted by antral G cells, histamine from enterochromaffin-like (ECL) cells, and acetylcholine from the vagus; somatostatin ($SST$) from antral D cells inhibits $G$ release and directly inhibits parietal cells.\n- Luminal acidity in the antrum normally stimulates D cells, increasing $SST$, which closes a negative feedback loop on $G$ and acid.\n- *Helicobacter pylori* produces urease, creating local alkalinization and inflammation that can selectively involve the antrum or corpus, altering $SST$ and $G$ signaling and, over time, parietal cell mass.\n\nWhich option best explains why an antral-predominant, non-atrophic *H. pylori* gastritis is more likely than corpus-predominant atrophy in this patient with a duodenal ulcer and elevated $BAO$?\n\nA. Antral-predominant *H. pylori* infection suppresses antral D-cell somatostatin via local alkalinization and inflammation, releasing inhibition on G cells, causing hypergastrinemia that drives ECL and parietal cell trophic changes and elevates basal and stimulated acid output; corpus atrophy would instead reduce parietal cell mass and lower $BAO$.\n\nB. Cytotoxin-associated gene A (CagA) from *H. pylori* directly activates parietal-cell proton pumps systemically, so corpus-predominant atrophy increases acid output and favors duodenal ulceration.\n\nC. Antral-predominant colonization primarily increases duodenal bicarbonate secretion, producing a compensatory rise in gastric acid output, whereas corpus atrophy spares acid output.\n\nD. Chronic pain from ulceration increases vagal tone, explaining elevated $BAO$ independent of gastritis pattern; antral-predominant and corpus atrophic gastritis are equally likely to produce hyperacidity.\n\nE. Corpus-predominant atrophic gastritis induces hypergastrinemia due to hypoacidity, which increases acid output enough to cause duodenal ulcers despite loss of parietal cells.",
            "solution": "The problem statement is a valid clinical and physiological query. It provides a detailed patient case and a set of fundamental principles of gastric physiology, asking for the best explanation of the patient's condition based on those principles.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n-   **Patient Data:** A 38-year-old man with recurrent epigastric pain relieved by food, presenting with a bleeding duodenal ulcer.\n-   **Endoscopic and Biopsy Findings:** A clean-based ulcer in the first portion of the duodenum. Biopsies from the gastric antrum are positive for *Helicobacter pylori* (*H. pylori*). No atrophic changes are seen in random biopsies from the proximal gastric corpus. Intrinsic factor antibodies are negative.\n-   **Laboratory Data:** Basal acid output (BAO) is elevated at 12 mEq/h. Fasting serum gastrin is modestly elevated.\n-   **Core Physiological Principles:**\n    1.  Gastric acid secretion by parietal cells is stimulated by gastrin ($G$), histamine, and acetylcholine.\n    2.  Somatostatin ($SST$) from antral D cells inhibits gastrin ($G$) release from G cells and also directly inhibits parietal cells.\n    3.  Luminal acidity in the antrum stimulates D cells, increasing $SST$ release (negative feedback).\n    4.  *H. pylori* produces urease, causing local alkalinization and inflammation, which can alter $SST$ and $G$ signaling and parietal cell mass.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective. The clinical presentation is a classic example of duodenal ulcer disease associated with *H. pylori*. The provided physiological principles are established facts in gastroenterology. The data are internally consistent: a duodenal ulcer is typically associated with acid hypersecretion, which is confirmed by the elevated BAO. The question asks for a mechanistic explanation linking the pattern of *H. pylori* infection to the observed pathophysiology, which is a standard problem in medical reasoning. There are no contradictions, ambiguities, or scientific inaccuracies in the problem setup.\n\n**Step 3: Verdict and Action**\nThe problem is valid. The solution process will proceed.\n\n**Derivation of the Correct Pathophysiological Mechanism**\n\nThe patient presents with a duodenal ulcer, an elevated basal acid output (BAO > 5 mEq/h is considered high, and this patient's is 12 mEq/h), and modest hypergastrinemia. His gastric corpus is non-atrophic. This clinical picture is one of acid hypersecretion. We must explain this using the given principles and determine whether an antral-predominant or corpus-predominant gastritis model fits these facts.\n\nLet's model the two scenarios based on the provided principles:\n\n1.  **Scenario 1: Antral-Predominant, Non-Atrophic Gastritis**\n    -   *H. pylori* colonizes the gastric antrum.\n    -   The bacteria's urease enzyme converts urea to ammonia ($\\text{NH}_3$), which buffers hydrogen ions ($\\text{H}^+$) to form ammonium ($\\text{NH}_4^+$). This creates a local \"cloud\" of higher pH (local alkalinization) around the bacteria.\n    -   The inflammatory response to *H. pylori* and this local alkalinization have a crucial effect on the antral endocrine cells. Specifically, they suppress or destroy the somatostatin-producing D cells.\n    -   According to principle #2, somatostatin ($SST$) is the primary inhibitor of gastrin ($G$) release from G cells.\n    -   With D cells suppressed, $SST$ levels decrease. This leads to the disinhibition (or release from inhibition) of the antral G cells.\n    -   The disinhibited G cells proliferate and hyper-secrete gastrin, leading to the observed modest hypergastrinemia.\n    -   According to principle #1, elevated gastrin has two major downstream effects:\n        a.  It acts as a trophic (growth) factor for the enterochromaffin-like (ECL) cells and parietal cells in the gastric corpus. Since the corpus is not infected/atrophic in this pattern, these cells are healthy and respond to the trophic stimulus, increasing the total parietal cell mass over time.\n        b.  It directly stimulates parietal cells and, more significantly, stimulates ECL cells to release histamine. Histamine is the most potent stimulant of acid secretion from parietal cells.\n    -   The combination of an increased parietal cell mass and chronic stimulation by the gastrin-histamine axis results in a significantly elevated basal acid output (BAO) and meal-stimulated acid output.\n    -   This chronic state of profound acid hypersecretion overwhelms the bicarbonate buffering capacity of the duodenal bulb, leading to mucosal injury and the formation of a duodenal ulcer.\n    -   This model perfectly aligns with all the patient's data: antral *H. pylori*, no corpus atrophy, high BAO, modest hypergastrinemia, and a duodenal ulcer.\n\n2.  **Scenario 2: Corpus-Predominant Atrophic Gastritis**\n    -   *H. pylori* infection is concentrated in the acid-secreting region of the stomach, the corpus (body).\n    -   Chronic, intense inflammation in this region leads to the destruction of gastric glands, including both the parietal cells (which produce acid) and ECL cells. This process is known as atrophic gastritis.\n    -   The destruction of parietal cells leads to a profound reduction in parietal cell mass.\n    -   Consequently, the stomach's capacity to secrete acid is severely diminished, resulting in hypochlorhydria (low acid) or achlorhydria (no acid). The BAO would be low, not high.\n    -   According to principle #3, the lack of acid in the stomach lumen removes the negative feedback stimulus for G cells. The G cells become markedly disinhibited, leading to severe hypergastrinemia (typically much higher than the \"modest\" elevation in duodenal ulcer disease).\n    -   Despite the very high gastrin levels, acid output remains low because the acid-producing \"factory\" (the parietal cells) has been destroyed.\n    -   This condition, pangastritis with atrophy, is associated with gastric ulcers and an increased risk of gastric adenocarcinoma, not duodenal ulcers.\n\n**Conclusion:** The antral-predominant, non-atrophic gastritis model is the only one that explains the patient's findings of a duodenal ulcer and elevated BAO.\n\n**Option-by-Option Analysis**\n\n**A. Antral-predominant H. pylori infection suppresses antral D-cell somatostatin via local alkalinization and inflammation, releasing inhibition on G cells, causing hypergastrinemia that drives ECL and parietal cell trophic changes and elevates basal and stimulated acid output; corpus atrophy would instead reduce parietal cell mass and lower BAO.**\nThis option accurately describes the full pathophysiological cascade for antral-predominant gastritis as derived above. It correctly identifies the suppression of $SST$-producing D cells, the resulting disinhibition of G cells and hypergastrinemia, the subsequent trophic effects on a healthy corpus, and the resultant acid hypersecretion. It also correctly contrasts this with the outcome of corpus atrophy, which involves loss of parietal cells and low acid output.\n**Verdict: Correct.**\n\n**B. Cytotoxin-associated gene A (CagA) from H. pylori directly activates parietal-cell proton pumps systemically, so corpus-predominant atrophy increases acid output and favors duodenal ulceration.**\nThis statement contains multiple errors. First, CagA does not directly activate proton pumps; its effects are mediated through complex intracellular signaling pathways related to inflammation and carcinogenesis. Second, its effects are not \"systemic\" in this manner. Third, and most critically, corpus-predominant atrophy *decreases* acid output due to loss of parietal cells; it does not increase it.\n**Verdict: Incorrect.**\n\n**C. Antral-predominant colonization primarily increases duodenal bicarbonate secretion, producing a compensatory rise in gastric acid output, whereas corpus atrophy spares acid output.**\nThis statement is incorrect on two counts. First, *H. pylori*-associated duodenitis is known to *impair* duodenal bicarbonate secretion, thereby reducing mucosal defense and contributing to ulcerogenesis. It does not increase it. Second, the claim that corpus atrophy \"spares acid output\" is false; it is the primary cause of reduced acid output in atrophic gastritis.\n**Verdict: Incorrect.**\n\n**D. Chronic pain from ulceration increases vagal tone, explaining elevated BAO independent of gastritis pattern; antral-predominant and corpus atrophic gastritis are equally likely to produce hyperacidity.**\nWhile vagal stimulation does increase acid secretion, it is not the principal explanation for the profound and chronic hypersecretion seen in this syndrome. The hormonal dysregulation (gastrin/somatostatin) is the dominant mechanism. The critical flaw is the assertion that corpus atrophic gastritis can produce hyperacidity; as established, it leads to hypoacidity.\n**Verdict: Incorrect.**\n\n**E. Corpus-predominant atrophic gastritis induces hypergastrinemia due to hypoacidity, which increases acid output enough to cause duodenal ulcers despite loss of parietal cells.**\nThis option starts correctly by stating that corpus atrophy leads to hypoacidity and compensatory hypergastrinemia. However, it then makes a logically inconsistent conclusion. High gastrin cannot stimulate acid production from cells that no longer exist. The \"loss of parietal cells\" (atrophy) makes it impossible for acid output to increase, let alone to a level that could cause a duodenal ulcer. Acid output would be low.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "A diagnostic test's raw sensitivity and specificity are important, but their clinical utility is truly realized through predictive values, which are critically dependent on the pre-test probability of disease. In managing *H. pylori*, where prevalence varies widely by geography and population, being able to calculate and interpret a test's performance in your specific setting is a fundamental skill. This practice will guide you through the derivation and calculation of positive and negative predictive values ($PPV$ and $NPV$) for the Rapid Urease Test (RUT), translating statistical theory into practical diagnostic insight .",
            "id": "4647825",
            "problem": "A clinician is evaluating the diagnostic performance of the Rapid Urease Test (RUT) for detecting *Helicobacter pylori* infection in adults undergoing upper endoscopy for dyspepsia in a population where the pre-test prevalence of infection is $0.40$. The RUT has sensitivity $0.90$ and specificity $0.95$. Using the definitions of sensitivity and specificity and Bayes' theorem with the law of total probability, derive expressions for the positive predictive value and negative predictive value in terms of the sensitivity, specificity, and prevalence, and compute their values for the given parameters. Express both the positive predictive value and the negative predictive value as decimals. Round your answers to four significant figures.",
            "solution": "The problem requires the derivation and computation of the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for a diagnostic test, given its sensitivity, specificity, and the prevalence of the condition in the population. We begin by formally defining the events and probabilities.\n\nLet $D$ be the event that an individual has the disease (*Helicobacter pylori* infection), and let $D^c$ be its complement, the event that the individual does not have the disease. Let $T$ be the event that the Rapid Urease Test (RUT) is positive, and let $T^c$ be its complement, a negative test result.\n\nThe given parameters are:\n1.  The prevalence of the infection, $P(D)$, which we denote by $p$. We are given $p = 0.40$.\n2.  The sensitivity of the test, $P(T|D)$, which we denote by $Se$. We are given $Se = 0.90$. This is the probability of a positive test for an individual who has the disease.\n3.  The specificity of the test, $P(T^c|D^c)$, which we denote by $Sp$. We are given $Sp = 0.95$. This is the probability of a negative test for an individual who does not have the disease.\n\nFrom these definitions, we can derive the probabilities of complementary events:\n-   The probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - p$.\n-   The false positive rate is the probability of a positive test given no disease: $P(T|D^c) = 1 - P(T^c|D^c) = 1 - Sp$.\n-   The false negative rate is the probability of a negative test given the presence of disease: $P(T^c|D) = 1 - P(T|D) = 1 - Se$.\n\nOur goal is to derive expressions for:\n-   The Positive Predictive Value, $PPV = P(D|T)$, which is the probability that an individual has the disease given that the test result is positive.\n-   The Negative Predictive Value, $NPV = P(D^c|T^c)$, which is the probability that an individual does not have the disease given that the test result is negative.\n\nWe shall use Bayes' theorem and the law of total probability.\n\n**Derivation of the Positive Predictive Value (PPV)**\nBy the definition of conditional probability, or Bayes' theorem, the PPV is:\n$$PPV = P(D|T) = \\frac{P(T|D) P(D)}{P(T)}$$\nThe term $P(T)$ in the denominator represents the total probability of obtaining a positive test result. This can be calculated using the law of total probability, by summing over the mutually exclusive states of having the disease or not:\n$$P(T) = P(T|D)P(D) + P(T|D^c)P(D^c)$$\nSubstituting the symbolic representations for prevalence, sensitivity, and specificity:\n$$P(T) = (Se)(p) + (1 - Sp)(1 - p)$$\nNow, substituting this expression for $P(T)$ back into the equation for PPV, we obtain the general formula:\n$$PPV = \\frac{Se \\cdot p}{Se \\cdot p + (1 - Sp)(1 - p)}$$\n\n**Derivation of the Negative Predictive Value (NPV)**\nSimilarly, the NPV is given by Bayes' theorem as:\n$$NPV = P(D^c|T^c) = \\frac{P(T^c|D^c) P(D^c)}{P(T^c)}$$\nThe denominator $P(T^c)$ is the total probability of a negative test result, which we expand using the law of total probability:\n$$P(T^c) = P(T^c|D)P(D) + P(T^c|D^c)P(D^c)$$\nSubstituting the symbolic representations:\n$$P(T^c) = (1 - Se)(p) + (Sp)(1 - p)$$\nSubstituting this expression for $P(T^c)$ into the equation for NPV, we get the general formula:\n$$NPV = \\frac{Sp \\cdot (1 - p)}{(1 - Se)p + Sp(1 - p)}$$\n\n**Numerical Computation**\nWe now substitute the given numerical values into the derived expressions: $p = 0.40$, $Se = 0.90$, and $Sp = 0.95$.\n\nFor the Positive Predictive Value:\n$$PPV = \\frac{(0.90)(0.40)}{(0.90)(0.40) + (1 - 0.95)(1 - 0.40)}$$\n$$PPV = \\frac{0.36}{0.36 + (0.05)(0.60)}$$\n$$PPV = \\frac{0.36}{0.36 + 0.03}$$\n$$PPV = \\frac{0.36}{0.39} = \\frac{12}{13} \\approx 0.9230769...$$\nRounding to four significant figures, we get $PPV = 0.9231$.\n\nFor the Negative Predictive Value:\n$$NPV = \\frac{(0.95)(1 - 0.40)}{(1 - 0.90)(0.40) + (0.95)(1 - 0.40)}$$\n$$NPV = \\frac{(0.95)(0.60)}{(0.10)(0.40) + (0.95)(0.60)}$$\n$$NPV = \\frac{0.57}{0.04 + 0.57}$$\n$$NPV = \\frac{0.57}{0.61} = \\frac{57}{61} \\approx 0.9344262...$$\nRounding to four significant figures, we get $NPV = 0.9344$.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.9231 & 0.9344 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Beyond diagnosis and treatment, a crucial aspect of managing chronic *H. pylori* gastritis is assessing the long-term risk of progression to gastric adenocarcinoma. The OLGA (Operative Link on Gastritis Assessment) and OLGIM (Operative Link on Gastric Intestinal Metaplasia) staging systems are powerful tools that standardize this risk assessment by systematically evaluating the extent and location of gastric atrophy and intestinal metaplasia. This problem provides a hands-on opportunity to apply these staging systems to a set of histological findings, a practical skill for determining patient prognosis and surveillance strategies .",
            "id": "4647830",
            "problem": "A patient with dyspepsia and confirmed *Helicobacter pylori* (*H. pylori*) infection undergoes gastric mapping biopsies according to the updated Sydney System: $2$ from the antrum (including the incisura angularis), $2$ from the corpus, and $1$ from the incisura angularis. Histology reports: moderate chronic inflammation in the antrum, no antral glandular atrophy, mild glandular atrophy in the corpus, and intestinal metaplasia limited to the antrum, involving fewer than $30\\%$ of antral glands, with no intestinal metaplasia in the corpus. Using the Operative Link on Gastritis Assessment (OLGA) and the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM), assign the stages and justify your choice by starting from foundational definitions of atrophy and intestinal metaplasia grading and their topographic distribution.\n\nWhich combination of OLGA and OLGIM stages is most appropriate?\n\nA. OLGA Stage $I$; OLGIM Stage $I$\n\nB. OLGA Stage $II$; OLGIM Stage $I$\n\nC. OLGA Stage $I$; OLGIM Stage $II$\n\nD. OLGA Stage $0$; OLGIM Stage $I$\n\nE. OLGA Stage $II$; OLGIM Stage $0$",
            "solution": "The problem statement will be validated before a solution is attempted.\n\n### Step 1: Extract Givens\n- **Patient Condition**: Dyspepsia and confirmed *Helicobacter pylori* (*H. pylori*) infection.\n- **Biopsy Protocol**: Gastric mapping biopsies according to the updated Sydney System.\n- **Biopsy Locations and Counts**: $2$ from the antrum (including the incisura angularis), $2$ from the corpus, and $1$ from the incisura angularis.\n- **Histology Findings (Atrophy)**:\n    - Antrum: No antral glandular atrophy.\n    - Corpus: Mild glandular atrophy.\n- **Histology Findings (Intestinal Metaplasia)**:\n    - Antrum: Intestinal metaplasia (IM) limited to the antrum, involving fewer than $30\\%$ of antral glands.\n    - Corpus: No intestinal metaplasia in the corpus.\n- **Task**: Assign stages using the Operative Link on Gastritis Assessment (OLGA) and the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) systems.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific Groundedness**: The problem is scientifically sound. It describes a standard clinical scenario in gastroenterology, utilizing established diagnostic procedures (Sydney System for biopsies) and risk stratification systems (OLGA, OLGIM) for patients with *H. pylori* gastritis. All terms and findings are medically and factually correct.\n2.  **Well-Posedness**: The problem is well-posed. The provided histological data are the direct inputs required for the OLGA and OLGIM staging algorithms. The staging systems are designed to yield a unique stage based on these inputs.\n3.  **Objectivity**: The problem is stated using objective, standard pathological terminology. Findings like \"mild glandular atrophy\" and \"fewer than $30\\%$\" are standard semi-quantitative assessments in histology.\n4.  **Completeness and Consistency**: The information provided is sufficient for staging. While the description of biopsy locations could be slightly clearer (the incisura angularis is mentioned twice), it reflects a robust sampling of the antrum. More importantly, the problem provides synthesized histological conclusions for the antrum and corpus, which is precisely the data needed. There are no contradictions.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. A solution will be derived.\n\n### Derivation of Solution\nThe solution requires applying the rules of the OLGA and OLGIM staging systems to the provided histological data. These systems stage chronic gastritis based on the topographic distribution (antrum vs. corpus) and severity of atrophy (OLGA) or intestinal metaplasia (OLGIM).\n\n**Foundational Definitions**\n\n1.  **Grading Atrophy and Intestinal Metaplasia**: The severity is typically graded on a percentage scale of the glandular mucosa involved in the biopsy specimens for a given location (antrum or corpus). A common scoring system is as follows:\n    - Score $0$: $0\\%$ involvement (absent)\n    - Score $1$: $1\\%$ to $30\\%$ involvement (mild)\n    - Score $2$: $31\\%$ to $60\\%$ involvement (moderate)\n    - Score $3$: $>60\\%$ involvement (severe)\n\n2.  **Staging**: The stage is determined by combining the highest scores from the antral and corporal biopsies in a matrix.\n\n**Analysis for OLGA Staging (Atrophy)**\n\nThe OLGA system stages gastritis based on the severity and location of glandular atrophy.\n\n-   **Antrum Atrophy**: The report states \"no antral glandular atrophy.\"\n    -   This corresponds to $0\\%$ involvement.\n    -   Antrum Atrophy Score = $0$.\n\n-   **Corpus Atrophy**: The report states \"mild glandular atrophy.\"\n    -   This corresponds to involvement between $1\\%$ and $30\\%$.\n    -   Corpus Atrophy Score = $1$.\n\n-   **OLGA Staging Matrix**: The stage is found at the intersection of the corpus score (row) and antrum score (column).\n\n| OLGA Staging | Antrum Atrophy Score ($0$) | Antrum Atrophy Score ($1$) | Antrum Atrophy Score ($2$) | Antrum Atrophy Score ($3$) |\n| :--- | :---: | :---: | :---: | :---: |\n| **Corpus Atrophy Score ($0$)** | Stage $0$ | Stage $I$ | Stage $II$ | Stage $II$ |\n| **Corpus Atrophy Score ($1$)** | Stage $I$ | Stage $II$ | Stage $III$ | Stage $III$ |\n| **Corpus Atrophy Score ($2$)** | Stage $II$ | Stage $III$ | Stage $IV$ | Stage $IV$ |\n| **Corpus Atrophy Score ($3$)** | Stage $III$ | Stage $IV$ | Stage $IV$ | Stage $IV$ |\n\nLocating the intersection for Corpus Score = $1$ and Antrum Score = $0$: the result is **OLGA Stage $I$**.\n\n**Analysis for OLGIM Staging (Intestinal Metaplasia)**\n\nThe OLGIM system stages gastritis based on the severity and location of intestinal metaplasia (IM).\n\n-   **Antrum Intestinal Metaplasia**: The report states \"intestinal metaplasia limited to the antrum, involving fewer than $30\\%$ of antral glands.\"\n    -   This corresponds to mild involvement.\n    -   Antrum IM Score = $1$.\n\n-   **Corpus Intestinal Metaplasia**: The report states \"no intestinal metaplasia in the corpus.\"\n    -   This corresponds to $0\\%$ involvement.\n    -   Corpus IM Score = $0$.\n\n-   **OLGIM Staging Matrix**: The stage is found at the intersection of the corpus IM score (row) and antrum IM score (column).\n\n| OLGIM Staging | Antrum IM Score ($0$) | Antrum IM Score ($1$) | Antrum IM Score ($\\ge 2$) |\n| :--- | :---: | :---: | :---: |\n| **Corpus IM Score ($0$)** | Stage $0$ | Stage $I$ | Stage $II$ |\n| **Corpus IM Score ($1$)** | Stage $I$ | Stage $II$ | Stage $III$ |\n| **Corpus IM Score ($\\ge 2$)** | Stage $II$ | Stage $III$ | Stage $IV$ |\n\nLocating the intersection for Corpus IM Score = $0$ and Antrum IM Score = $1$: the result is **OLGIM Stage $I$**.\n\n**Conclusion**\nBased on the provided histological findings, the patient's gastritis is classified as OLGA Stage $I$ and OLGIM Stage $I$.\n\n### Option-by-Option Analysis\n\n-   **A. OLGA Stage $I$; OLGIM Stage $I$**:\n    -   The OLGA Stage $I$ is correctly derived from mild corpus atrophy (Score $1$) and no antral atrophy (Score $0$).\n    -   The OLGIM Stage $I$ is correctly derived from mild antral intestinal metaplasia (Score $1$) and no corpus intestinal metaplasia (Score $0$).\n    -   Verdict: **Correct**.\n\n-   **B. OLGA Stage $II$; OLGIM Stage $I$**:\n    -   OLGA Stage $II$ is incorrect. This stage would require more advanced atrophy, such as moderate antral atrophy (Score $2$) and no corpus atrophy (Score $0$), or mild atrophy in both corpus and antrum (Score $1$ for both). The patient's findings do not meet these criteria.\n    -   Verdict: **Incorrect**.\n\n-   **C. OLGA Stage $I$; OLGIM Stage $II$**:\n    -   OLGIM Stage $II$ is incorrect. This stage would require either moderate-to-severe antral IM (Score $\\ge 2$) alone, or any IM in the corpus (Score $>0$) with any IM in the antrum (Score $>0$). The patient has only mild antral IM (Score $1$) and no corpus IM.\n    -   Verdict: **Incorrect**.\n\n-   **D. OLGA Stage $0$; OLGIM Stage $I$**:\n    -   OLGA Stage $0$ is incorrect. This stage requires the complete absence of atrophy in both the antrum and the corpus (Score $0$ for both). The patient has mild corpus atrophy (Score $1$).\n    -   Verdict: **Incorrect**.\n\n-   **E. OLGA Stage $II$; OLGIM Stage $0$**:\n    -   OLGA Stage $II$ is incorrect (see analysis for option B).\n    -   OLGIM Stage $0$ is incorrect. This stage requires the complete absence of intestinal metaplasia in both the antrum and the corpus. The patient has mild IM in the antrum.\n    -   Verdict: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}